Tevogen Bio discusses AI in drug development at J.P. Morgan Healthcare Conference

From GlobeNewswire: 2025-01-23 19:53:05

Tevogen Bio Holdings Inc. shared insights from the J.P. Morgan Healthcare Conference, highlighting the use of AI and ML for cost and time efficiencies in drug development. Microsoft’s Global CMO and Tevogen.AI’s CIO discussed AI’s impact on healthcare delivery. Dr. Rhew emphasized AI’s role in accelerating drug discovery by reducing time to identify drug candidates. Both speakers discussed the rise of generative AI and multimodal data, emphasizing the need for data quality and responsible AI development practices. Tevogen Bio focuses on developing precision T cell therapies for various diseases to address unmet patient needs and advance medical innovation.



Read more at GlobeNewswire: Tevogen Bio Highlights the Future of AI-Driven Drug